<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156510">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02044692</url>
  </required_header>
  <id_info>
    <org_study_id>GC1111_OS</org_study_id>
    <nct_id>NCT02044692</nct_id>
  </id_info>
  <brief_title>The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients</brief_title>
  <official_title>The Long-term Safety of Hunterase (Idursulfase-beta) in Hunter Syndrome(Mucopolysaccharidosis II) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the long term safety and efficacy of once weekly
      dosing of idurasulfase-beta 0.5mg/kg administered  in Hunter Syndrome(Mucopolysaccharidosis
      II) Patients
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Incidence of adverse event and adverse drug reaction.</measure>
    <time_frame>Once a week up to 5years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of vital sign, physical and clinical examination, anti-idurasulfase-beta antibody status.</measure>
    <time_frame>Base line and every three months up to 5years.(exception: clinical examination-&gt; baseline and every six months up to 5years)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Percent change of urine GAG.</measure>
    <time_frame>Baseline and every three months up to 5years.</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Percent change of 6 minute walking test.</measure>
    <time_frame>Baseline and every 6 months up to 5years.</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Hunter Syndrome</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Hunter Syndrome(Mucopolysaccharidosis II) Patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have a diagnosis of Hunter syndrome(Mucopolysaccharidosis II).

          -  Patients who are administered idurasulfase-beta or willing to be administered
             idurasulfase-beta.

          -  Patient's parent(s), or patient's legal guardian must have given voluntary written
             consent to participate in the study.

        Exclusion Criteria:

          -  Patients who have participated in any other blind clinical trials.

          -  Patient who cannot be tracked about safety.

          -  Patients who are judged disqualified to participate clinical trials by investigator
             for other causes.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong-Kyu Jin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung medical center, Seoul, Republic of Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong-Kyu Jin</last_name>
    <email>jindk.jin@samsung.com</email>
  </overall_contact>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 22, 2014</lastchanged_date>
  <firstreceived_date>January 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hunter syndrome</keyword>
  <keyword>Mucopolysaccharidosis II</keyword>
  <keyword>Hunterase</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
